Work

Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, Is Clinically Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Year: 2014

Type: article

Source: Blood

DOI: 10.1182/blood.v124.21.3334.3334

Authors: Susan O'Brien, Manish Patel, Brad S. Kahl, Steven M. Horwitz, Francine M. Foss, Pierluigi Porcu, Jennifer Sweeney, Kerstin Allen, Kerrie Faia, Howard M. Stern, Patrick Kelly, Ian Flinn

Institutions: The University of Texas MD Anderson Cancer Center, Sarah Cannon, University of Wisconsin–Madison, Memorial Sloan Kettering Cancer Center, Yale University, The Ohio State University Wexner Medical Center, Infinity Pharmaceuticals (United States)

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2341725288

FWCI: 8.351

Cites:

Cited by: 65

Related to: 10